Naltrexone, Suboxone, Methadone: How Medications Treat Opioid Addiction
6/25/202654 min
Is willpower alone enough to beat opioid addiction, or are we fighting a medical disease with the wrong tools? In this episode of the Recoverable podcast, we shift the paradigm from shame to evidence-based science.
Find mental health and addiction treatment near you: https://recovery.com/
Host Terry Maguire sits down with Dr. Stephen Klein, MD, PhD, a triple-boarded physician in pediatrics, genetics, and addiction medicine who serves as full-time faculty at Caron Treatment Centers. Dr. Klein brings a deeply authentic perspective to the table as a professional in long-term recovery himself, diving into the raw mechanics of Medications for Opioid Use Disorder (MOUD). We break down the crucial differences between traditional Medication-Assisted Treatment (MAT) and OUD-specific options like Suboxone (buprenorphine/naloxone), oral naltrexone, and the game-changing shift toward monthly long-acting injectables.
Dr. Klein directly confronts the intense societal stigma and the ongoing debate within 12-step recovery groups like Alcoholics Anonymous (AA) and Narcotics Anonymous (NA) over whether using addiction medication means you are truly "sober". He shares the striking clinical data regarding the low number needed to treat (NNT) for buprenorphine compared to other lifelines in modern medicine. Beyond the blocking of withdrawal symptoms and cravings, we uncover the profound psychological "why" behind substance abuse—looking closely at trauma, identity, and the heavy sense of disconnection that fuels severe opioid use disorder. If you or a loved one are trying to navigate rehab options, outpatient detox programs, or sober living rules, this conversation offers data-backed hope. Subscribe for Part 2 next week, and leave a comment below with your thoughts!
Chapters:
00:00 – Changing the Paradigm of Addiction Recovery
01:11 – Dr. Stephen Klein’s Personal Recovery Journey
03:36 – What is the Difference Between MAT and MOUD?
05:12 – The Opioid Class: From Prescription Pills to Kratom
07:05 – Is Abstinence Always the Goal of MOUD Treatment?
09:28 – How Do We Measure Success in Addiction Recovery?
11:34 – How Suboxone and Naltrexone Block Cravings
14:56 – Navigating Stigma: "Replacing One Drug with Another"
21:16 – How Monthly Injectables Change Compliance and Self-Stigma
23:55 – The True Medical Risks of Untreated Opioid Withdrawal
Questions the Video Answers:
What is the difference between MAT and MOUD in addiction treatment?
How does Suboxone (buprenorphine/naloxone) work for opioid addiction?
Can you use naltrexone for both opioid and alcohol use disorder?
Why do 12-step programs like AA and NA stigmatize Suboxone users?
How do monthly injectable addiction medications like Vivitrol reduce self-stigma?
What is the Sinclair Method for treating alcohol use disorder?
Is a person on MOUD considered truly sober and in recovery?
What are the side effects of buprenorphine vs untreated opioid withdrawal?
Does health insurance or Medicaid cover long-acting injectable opioid treatments?
Why is kratom considered an emerging and dangerous opioid alkaloid?
How do trauma and deep emotional disconnection cause substance abuse?
How can family members support a loved one starting buprenorphine?
#OpioidAddiction #SuboxoneRecovery #AddictionMedicine
Clips
Transcript preview
First 90 secondsSteven Kline· Guest0:00
Addiction is a high morbidity, high mortality disease. The risk of not taking MOUD for severe opioid use disorder in the most extreme is death from overdose.
Terri McGuire· Host0:10
Dr. Steven Kline, who specializes in addiction medicine, joins us to discuss innovative treatments, including the role of GLP-1s in substance use disorder recovery.
Steven Kline· Guest0:20
I actually don't think there's anything lazy about being on buprenorphine. I use the word heroic a lot. My patients are incredibly heroic and incredibly courageous.
Terri McGuire· Host0:29
[keyboard typing] Welcome to Recoverable. I'm your host, Terri McGuire. Today, we begin our discussion about pharmaceutical interventions for addiction recovery. In part one, we're gonna take a deep dive into medications for opioid use disorders, or MOUD's. And in part two next week, we will shift focus to the frontier of science as we investigate the emerging role of GLP-1s in curbing cravings beyond just metabolic health. It's an essential conversation about shifting the paradigm from willpower to evidence-based clinical treatment. Dr. Steven Kline, a prominent figure in the field, is gonna join us in the studio and share his expertise on the topic. Welcome.
Steven Kline· Guest1:10
Thank you for having me.
Terri McGuire· Host1:11
Thank you for being here. Before we dive into the Internet's top questions, I would love to know a bit about you and what it is that propelled you into this field, of all the things you could have chosen.
Steven Kline· Guest1:21
My background is actually a little bit unique for someone who practices addiction medicine. So from a medical perspective, I've had a lot of training